231 related articles for article (PubMed ID: 26933761)
1. Hyperthermia adds to trabectedin effectiveness and thermal enhancement is associated with BRCA2 degradation and impairment of DNA homologous recombination repair.
Harnicek D; Kampmann E; Lauber K; Hennel R; Cardoso Martins AS; Guo Y; Belka C; Mörtl S; Gallmeier E; Kanaar R; Mansmann U; Hucl T; Lindner LH; Hiddemann W; Issels RD
Int J Cancer; 2016 Jul; 139(2):467-79. PubMed ID: 26933761
[TBL] [Abstract][Full Text] [Related]
2. Analysis of DNA repair-related genes in breast cancer reveals CUL4A ubiquitin ligase as a novel biomarker of trabectedin response.
García MJ; Saucedo-Cuevas LP; Muñoz-Repeto I; Fernández V; Robles MJ; Domingo S; Palacios J; Aracil M; Nieto A; Tercero JC; Benítez J
Mol Cancer Ther; 2013 Apr; 12(4):530-41. PubMed ID: 23364677
[TBL] [Abstract][Full Text] [Related]
3. Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair.
Lima M; Bouzid H; Soares DG; Selle F; Morel C; Galmarini CM; Henriques JA; Larsen AK; Escargueil AE
Oncotarget; 2016 May; 7(18):25885-901. PubMed ID: 27029031
[TBL] [Abstract][Full Text] [Related]
4. Role of homologous recombination in trabectedin-induced DNA damage.
Tavecchio M; Simone M; Erba E; Chiolo I; Liberi G; Foiani M; D'Incalci M; Damia G
Eur J Cancer; 2008 Mar; 44(4):609-18. PubMed ID: 18243687
[TBL] [Abstract][Full Text] [Related]
5. The effect of thermal dose on hyperthermia-mediated inhibition of DNA repair through homologous recombination.
van den Tempel N; Laffeber C; Odijk H; van Cappellen WA; van Rhoon GC; Franckena M; Kanaar R
Oncotarget; 2017 Jul; 8(27):44593-44604. PubMed ID: 28574821
[TBL] [Abstract][Full Text] [Related]
6. Trabectedin as a chemotherapy option for patients with BRCA deficiency.
Monk BJ; Lorusso D; Italiano A; Kaye SB; Aracil M; Tanović A; D'Incalci M
Cancer Treat Rev; 2016 Nov; 50():175-182. PubMed ID: 27710871
[TBL] [Abstract][Full Text] [Related]
7. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
[TBL] [Abstract][Full Text] [Related]
8. BRCA2 protects mammalian cells from heat shock.
Nakagawa Y; Kajihara A; Takahashi A; Murata AS; Matsubayashi M; Ito SS; Ota I; Nakagawa T; Hasegawa M; Kirita T; Ohnishi T; Mori E
Int J Hyperthermia; 2018 Sep; 34(6):795-801. PubMed ID: 28891354
[TBL] [Abstract][Full Text] [Related]
9. Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas.
Laroche A; Chaire V; Le Loarer F; Algéo MP; Rey C; Tran K; Lucchesi C; Italiano A
J Hematol Oncol; 2017 Apr; 10(1):84. PubMed ID: 28399901
[TBL] [Abstract][Full Text] [Related]
10. Enhanced G2/M Arrest, Caspase Related Apoptosis and Reduced E-Cadherin Dependent Intercellular Adhesion by Trabectedin in Prostate Cancer Stem Cells.
Acikgoz E; Guven U; Duzagac F; Uslu R; Kara M; Soner BC; Oktem G
PLoS One; 2015; 10(10):e0141090. PubMed ID: 26485709
[TBL] [Abstract][Full Text] [Related]
11. BRCA2 is needed for both repair and cell cycle arrest in mammalian cells exposed to S23906, an anticancer monofunctional DNA binder.
Rocca CJ; Soares DG; Bouzid H; Henriques JA; Larsen AK; Escargueil AE
Cell Cycle; 2015; 14(13):2080-90. PubMed ID: 25945522
[TBL] [Abstract][Full Text] [Related]
12. Trabectedin is a promising antitumor agent potentially inducing melanocytic differentiation for clear cell sarcoma.
Nakai T; Imura Y; Tamiya H; Yamada S; Nakai S; Yasuda N; Kaneko K; Outani H; Takenaka S; Hamada K; Myoui A; Araki N; Ueda T; Itoh K; Yoshikawa H; Naka N
Cancer Med; 2017 Sep; 6(9):2121-2130. PubMed ID: 28745431
[TBL] [Abstract][Full Text] [Related]
13. Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.
Hoda MA; Pirker C; Dong Y; Schelch K; Heffeter P; Kryeziu K; van Schoonhoven S; Klikovits T; Laszlo V; Rozsas A; Ozsvar J; Klepetko W; Döme B; Grusch M; Hegedüs B; Berger W
Mol Cancer Ther; 2016 Oct; 15(10):2357-2369. PubMed ID: 27512118
[TBL] [Abstract][Full Text] [Related]
14. PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models.
Pignochino Y; Capozzi F; D'Ambrosio L; Dell'Aglio C; Basiricò M; Canta M; Lorenzato A; Vignolo Lutati F; Aliberti S; Palesandro E; Boccone P; Galizia D; Miano S; Chiabotto G; Napione L; Gammaitoni L; Sangiolo D; Benassi MS; Pasini B; Chiorino G; Aglietta M; Grignani G
Mol Cancer; 2017 Apr; 16(1):86. PubMed ID: 28454547
[TBL] [Abstract][Full Text] [Related]
15. Von Hippel-Lindau-coupled and transcription-coupled nucleotide excision repair-dependent degradation of RNA polymerase II in response to trabectedin.
Aune GJ; Takagi K; Sordet O; Guirouilh-Barbat J; Antony S; Bohr VA; Pommier Y
Clin Cancer Res; 2008 Oct; 14(20):6449-55. PubMed ID: 18927284
[TBL] [Abstract][Full Text] [Related]
16. Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin.
Casado JA; Río P; Marco E; García-Hernández V; Domingo A; Pérez L; Tercero JC; Vaquero JJ; Albella B; Gago F; Bueren JA
Mol Cancer Ther; 2008 May; 7(5):1309-18. PubMed ID: 18483318
[TBL] [Abstract][Full Text] [Related]
17. Enhancing radiosensitisation of BRCA2-proficient and BRCA2-deficient cell lines with hyperthermia and PARP1-i.
Oei AL; Ahire VR; van Leeuwen CM; Ten Cate R; Stalpers LJA; Crezee J; Kok HP; Franken NAP
Int J Hyperthermia; 2018 Feb; 34(1):39-48. PubMed ID: 28540821
[TBL] [Abstract][Full Text] [Related]
18. Unique features of trabectedin mechanism of action.
Larsen AK; Galmarini CM; D'Incalci M
Cancer Chemother Pharmacol; 2016 Apr; 77(4):663-71. PubMed ID: 26666647
[TBL] [Abstract][Full Text] [Related]
19. Trabectedin mechanism of action and platinum resistance: molecular rationale.
Ray-Coquard I
Future Oncol; 2017 Oct; 13(23s):17-21. PubMed ID: 29020822
[TBL] [Abstract][Full Text] [Related]
20. Zalypsis (PM00104) is a potent inducer of gamma-H2AX foci and reveals the importance of the C ring of trabectedin for transcription-coupled repair inhibition.
Guirouilh-Barbat J; Antony S; Pommier Y
Mol Cancer Ther; 2009 Jul; 8(7):2007-14. PubMed ID: 19584237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
